The physiologic activator of factor X consists of a complex of factor IXa, factor VIIIa, Ca 2؉ and a suitable phospholipid surface. In one study, helix 330 (162 in chymotrypsin) of the protease domain of factor IXa was implicated in binding to factor VIIIa. In another study, residues 558 -565 of the A2 subunit of factor VIIIa were implicated in binding to factor IXa. We now provide data, which indicate that the helix 330 of factor IXa interacts with the 558 -565 region of the A2 subunit. Thus, the ability of the isolated A2 subunit was severely impaired in potentiating factor X activation by IXa R333Q and by a helix replacement mutant (IXa helixVII in which helix 330 -338 is replaced by that of factor VII) but it was normal for an epidermal growth factor 1 replacement mutant (IXa PCEGF1 in which epidermal growth factor 1 domain is replaced by that of protein C). Further, affinity of each 5-dimethylaminonaphthalene-1-sulfonyl (dansyl)-Glu-Gly-Arg-IXa (dEGR-IXa) with the A2 subunit was determined from its ability to inhibit wild-type IXa in the tenase assay and from the changes in dansyl fluorescence emission signal upon its binding to the A2 subunit. Apparent K d(A2) values are: dEGR-IXa WT or dEGR-IXa PCEGF1 ϳ100 nM, dEGR-IXa R333Q ϳ1.8 M, and dEGR-IXa helixVII >10 M. In additional experiments, we measured the affinities of these factor IXa molecules for a peptide comprising residues 558 -565 of the A2 subunit. Apparent K d(peptide) values are: dEGR-IXa WT or dEGRIXa PCEGF1 ϳ4 M, and dEGR-IXa R333Q ϳ62 M. Thus as compared with the wild-type or PCEGF1 mutant, the affinity of the R333Q mutant for the A2 subunit or the A2 558 -565 peptide is similarly reduced. These data support a conclusion that the helix 330 of factor IXa interacts with the A2 558 -565 sequence. This information was used to model the interface between the IXa protease domain and the A2 subunit, which is also provided herein.
Physiologic blood clotting begins by exposure of blood to tissue factor (TF) 1 at an injury site and formation of the complex between TF and plasma factor VIIa. The TF⅐VIIa complex formed activates both factors IX and X (1, 2) . Factor IXa thus generated forms a stoichiometric complex with factor VIIIa and also activates factor X in the presence of Ca 2ϩ and a suitable phospholipid (PL) surface (1, 2) . The role of factor VIIIa in this complex is to increase the k cat by several orders of magnitude while PL primarily reduces the K m for the substrate factor X.
Human factor IX circulates in blood as a single chain protein of 415 amino acids. Upon activation (by factor XIa/Ca 2ϩ or TF⅐VIIa/Ca 2ϩ ), two peptide bonds in factor IX are cleaved with resultant formation of a serine protease, factor IXa, and release of an activation peptide (3) . Factor IXa is composed of a light chain consisting of residues 1-145 and a heavy chain consisting of residues 181-415 of native factor IX, that are held together by a single disulfide bond (4, 5) . The light chain of factor IXa consists of an amino-terminal ␥-carboxyglutamic acid (Gla)-rich domain (residues 1-40), a short hydrophobic segment (residues [41] [42] [43] [44] [45] [46] , and two epidermal growth factor (EGF)-like domains (EGF1 residues 47-84 and EGF2 residues 85-127), whereas the heavy chain contains the serine protease domain, which features the catalytic triad residues, namely His 221 (c57), 2 Asp 269 (c102), and Ser 365 (c195) (5) . The Gla domain contains several high and low affinity Ca 2ϩ -binding sites, whereas EGF1 and protease domain each contain a high affinity Ca 2ϩ site (7) . For proper binding of factor IXa to PL and factor VIIIa, all of the Ca 2ϩ sites in factor IXa must be filled (7, 8) .
Factor VIII is synthesized as a single chain molecule containing several domains (A1-A2-B-A3-C1-C2) (9) , with a molecular mass of ϳ300 kDa (10, 11) . The A domains are homologous to the ceruloplasmin domains and to the A domains of factor Va (12) , whereas the C domains are homologous to the galactose lipid binding domain and to the regions within neuraminidase (13) . Factor VIII circulates as a divalent metal ion-dependent, noncovalent heterodimer resulting from proteolytic cleavage at the B/A3 junction that generates a heavy chain (A1-A2-B) and a light chain (A3-C1-C2 * This work was supported by National Institutes of Health Grant HL36365 and American Heart Association Grant 9950228N (both to S. P. B.) and by National Institutes of Health Grants HL30616 and HL38199 (to P. J. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed: Div. of Hematology and Oncology, Saint Louis University Health Sciences Center, 3635 Vista Ave., P.O. Box 15250, St. Louis, MO 63110-0250. Tel.: 314-577-8499/8854; Fax: 314-773-1167; E-mail: bajajps@slu.edu. 1 The abbreviations used are: TF, tissue factor; Gla, ␥-carboxyglutamic acid; EGF, epidermal growth factor; PL, phospholipid; BSA, bovine serum albumin; WT, wild type; TBS, Tris-buffered saline; dansyl, 5-dimethylaminonaphthalene-1-sulfonyl; dEGR-ck, dansyl-Glu-GlyArg-chloromethyl ketone; dEGR-IXa, IXa inactivated with dEGR-ck; S-2222, benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide; NP, normal plasma; K d(A2) , dissociation constant for dEGR-IXa and the A2 subunit; K d(peptide) , dissociation constant for factor IXa and the A2 558 -565 peptide; TBS, Tris-buffered saline; PAGE, polyacrylamide gel electrophoresis. 2 For comparison, the factor IX amino acid numbering system is used. The numbers with a prefix c (e.g. c57) in parentheses refer to the chymotrypsin equivalents for the protease domain of factor IXa (6).
to yield factor VIIIa, a heterotrimer composed of A1, A2, and A3-C1-C2 subunits (14, 15) . The A1 and A3-C1-C2 subunits remain associated with a divalent metal ion-dependent linkage, whereas the A2 subunit is weakly associated with the A1 and A3-C1-C2 dimer (16, 17) . Although intact factor VIIIa is required for maximal enhancement of factor IXa activity, recent results demonstrate that the isolated A2 subunit stimulates factor IXa activity by ϳ100-fold (18) . Ca 2ϩ -dependent assembly of factor IXa and factor VIIIa on a suitable PL surface is essential for hemostasis since defects or deficiency in the proteins result in severe bleeding diatheses, namely hemophilia A (factor VIII deficiency) or hemophilia B (factor IX deficiency) (Ref. 12; see the hemophilia A mutation data base and the Haemophilia B data base of point mutations and short additions and deletions, both available via the World Wide Web). In this assembly, the Ca 2ϩ -loaded form of the Gla domain of factor IXa binds to PL (21), whereas EGF1 3 /EGF2 region(s) and the protease domain are thought to interact with the A3 and A2 subunits of factor VIIIa, respectively (18, 22) . Factor VIIIa in this assembly anchors to the PL surface via its C2 domain (13) , and binding of factor X to the IXa/VIIIa complex may be partly mediated through the A1 subunit of factor VIIIa (23) .
In the IXa/VIIIa complex, residues 558 -565 of the A2 subunit of factor VIIIa are thought to bind to the protease domain of factor IXa (24) . Further, helix 330 -338 (c162-170) of the protease domain of factor IXa has been shown to bind to factor VIIIa (25) . However, whether or not helix 330 -338 of factor IXa binds to the A2 subunit or more specifically to its 558 -565 peptide region is not known. The present study is designed to address this issue. The kinetic, fluorescence, and inhibition data indicate that helix 330 (c162) of factor IXa most likely interacts with the 558 -565 region of the A2 subunit. An interface model between the helix 330 -338 of factor IXa and the A2 558 -565 region was then constructed. Other spatially nearby residues in factor IXa as well as those in the A2 subunit that could contribute to the interface were noted. The role of these residues in this interaction is discussed.
EXPERIMENTAL PROCEDURES
Reagents-Benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide (S-2222) was purchased from Helena Laboratories. Dansyl-Glu-Gly-Arg-chloromethyl ketone (dEGR-ck) was obtained from Calbiochem. Phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, recombinant hirudin, and fatty acid-free bovine serum albumin (BSA) were obtained from Sigma. PL vesicles containing 75% phosphatidylcholine and 25% phosphatidylserine were prepared by the method of Husten et al. (26) and used for all experiments except for the fluorescence emission studies. For fluorescence experiments, PL vesicles comprised 40% phosphatidylcholine, 20% phosphatidylserine, and 40% phosphatidylethanolamine and were prepared using octyl glucoside as described (27) . Recombinant factor VIII preparations (Kogenate ® ) were a gift from Drs. Lisa Regan and Jim Brown of Bayer Corp.. Purified recombinant factor VIII was also a generous gift from Debra Pittman of the Genetics Institute. Normal plasma factor IX (IX NP ) and factor X were isolated as described (6) , and factor Xa was prepared as outlined (28) . Purified human factor XIa and ␣-thrombin were purchased from Enzyme Research Laboratories (South Bend, IN). A synthetic peptide corresponding to the A2 subunit residues 558 -565 (Ser-Val-Asp-Gln-Arg-Gly-Asn-Gln) was obtained as described previously (18) , and its concentration was determined by amino acid analysis.
Proteins-The Kogenate ® concentrate was fractionated to separate factor VIII from albumin following S-Sepharose chromatography as outlined (29) . Factor VIIIa was prepared from factor VIII using thrombin and subsequently purified using CM-Sepharose chromatography (30) , and the A2 subunit and A1/A3-C1-C2 dimer were separated by Mono S chromatography (15) . The A2 subunit was further purified using an anti-A2 immunoaffinity column (15) . The purified A2 subunit was essentially homogeneous (Ͼ95% pure), as judged by SDS-PAGE. For some experiments, proteins were concentrated using a Microcon concentrator (Millipore, 10-kDa cut-off). The concentration of the A2 subunit was determined by the Coomassie Blue dye binding method of Bradford (31) . Wild-type factor IX (IX WT ), as well as mutants IX R333Q (a point mutant in which R333 is replaced by Gln), IX VIIhelix (a replacement mutant in which helix 330 -338 (c162-170) is replaced by that of factor VII), and IX PCEGF1 (a replacement mutant in which EGF1 domain is replaced by that of protein C), were constructed, expressed, and purified as described previously (25, 32, 33) . Purified proteins were homogeneous on SDS-PAGE and contained normal Gla content (25, 32) .
Preparation of dEGR-ck-inhibited Factor IXa Proteins-Each factor IX protein was activated at 200 g/ml by factor XIa (2 g/ml) for 90 min. The buffer used was TBS, pH 7.5 (50 mM Tris, 150 mM NaCl, pH 7.5), containing 5 mM CaCl 2 . SDS-PAGE analysis revealed full activation of each factor IX to factor IXa without degradation in the autolysis loop (34) . dEGR-IXa WT and various dEGR-IXa mutant proteins free of dEGR-ck were obtained as described previously (34) .
Activation of Factor X by Each Factor IXa Protein in the Presence of Ca 2ϩ and PL-For these studies, each factor IX was activated with factor XIa/Ca 2ϩ as described above. For factor X activation studies, the concentration of factor IXa was kept at 20 nM and the buffer used was TBS/BSA (TBS with 200 g/ml BSA) containing 5 mM CaCl 2. The concentrations of PL used were 10, 25, 50, and 100 M in different sets of experiments. The concentration of factor X at each PL concentration ranged from 25 nM to 3 M. The activations were carried out for 5-15 min, and the amount of factor Xa generated was measured by hydrolysis of S-2222 as described previously (25, 34) . The K m and k cat values were obtained using the program GraFit from Erithacus Software.
Determination of EC 50 of Interaction of factor IXa Proteins with the A2 Subunit-The EC 50 (functional K d ) of binding of each factor IXa protein with the A2 subunit was measured essentially as described previously for its interaction with the intact factor VIIIa (25, 34) . For these experiments, concentrations of factor IXa and factor X were kept constant, and the rates of formation of factor Xa were determined at increasing concentrations of the A2 subunit. Reaction mixtures contained 5 nM factor IXa, 250 nM factor X, 25 M PL, and various concentrations of the A2 subunit in TBS/BSA, pH 7.5 containing 5 mM CaCl 2 . Reactions were carried out at 37°C for 5-20 min and stopped by adding 1 l of 500 mM EDTA. The amount of factor Xa generated was determined by S-2222 hydrolysis as described previously (25, 34) . The EC 50 was obtained by fitting the data to a single-site ligand binding equation (Equation 1) by non-linear regression analysis using the program GraFit from Erithacus Software.
V is the rate of formation of factor Xa at a given concentration of the A2 subunit, denoted by L, and V max is the rate of factor Xa formation by the factor IXa:A2 subunit complex. EC 50 is the functional K d defined as the concentration of free A2 subunit yielding 50% of the V max . The background rate of factor Xa generation was obtained by carrying out the reaction in the absence of the A2 subunit. This represented less than 1% of the V max and was subtracted before data analysis. To obtain EC 50 values as a function of substrate concentration, a series of experiments were performed in which factor X was varied from 50 nM to 1 M.
Determination of the Apparent K d(A2) of Binding of dEGR-IXa Proteins to the A2 Subunit-The
) for binding of each dEGR-IXa protein to the A2 subunit was determined by its ability to inhibit factor IXa WT :A2 subunit interaction in the tenase complex as described previously for intact factor VIIIa (25, 34) . The reactions were carried out as described for the EC 50 experiments above, except that the dEGR-IXa and IXa WT were mixed prior to addition of the A2 subunit; this ensured steady state conditions. Mixtures contained 100 nM IXa WT , 30 nM A2 subunit, 250 nM factor X, 25 M PL, and various concentrations of dEGR-IXa proteins in TBS/BSA, pH 7.5 containing 5 mM CaCl 2 . The IC 50 (concentration of inhibitor required for 50% inhibition) was determined by fitting the data to IC 50 four-parameter logistic equation of Halfman (35) given below.
y is the rate of factor Xa formation in the presence of a given concentration of dEGR-IXa protein represented by x, a is the maximum rate of factor Xa formation in the absence of dEGR-IXa, and s is the slope factor. Each point was weighted equally, and the data were fitted to Equation 2 using the nonlinear regression analysis program GraFit from Erithacus Software. The background value represented ϳ5% of the maximum rate of factor Xa formation in the absence of dEGR-IXa. To obtain apparent K d(A2) values for the interaction of dEGR-IXa proteins with A2, we used the following equation as described by Cheng and Prusoff (36) and further elaborated by Craig (37) .
A is the concentration of factor IXa WT , and EC 50 is the concentration of factor IXa WT that gives a 50% maximum response in the absence of the competitor at a specified concentration of factor X used in the experiment.
Fluorescence Quenching of the Dansyl Moiety in dEGR-
IXa by the A2 Subunit-Effect of the A2 subunit on the emission intensity of the dansyl moiety in each dEGR-IXa protein was determined using the SLM AB2 spectrofluorometer. Each reaction mixture contained 220 nM dEGR-IXa in 20 mM Hepes, pH 7.2, 100 mM NaCl, 5 mM CaCl 2 , 0.01% Tween, 200 g/ml BSA, and 100 M PL vesicles. The excitation wavelength was 340 nm (slit width, 8 nm) and the emission wavelength was 540 nm (slit width, 8 nm). First, blank values (in triplicate) were obtained for the buffer containing PL. dEGR-IXa was then added, and the emission intensity in the absence of the A2 subunit was recorded. Each reaction mixture was subsequently titrated with the A2 subunit, and the emission readings (in triplicate) were obtained at each point. The fluorescence emission intensity at each point was corrected for increases in the reaction volume prior to analysis of the data. The volume of added A2 subunit did not exceed 10% of the total volume. Data are presented as F/F 0 , where F 0 is the emission intensity in the absence of A2 subunit and F is the intensity at a given A2 subunit concentration.
Determination of the Apparent K d(peptide) of binding of each factor IXa to the A2 558 -565 peptide-The
for binding of each factor IXa to the A2 558 -565 peptide was determined by its ability to inhibit the respective IXa:A2 subunit interaction, as measured by reduction in the rate of factor X activation in the tenase system. The reaction mixtures for both IXa WT and IXa PCEGF1 contained 100 nM factor IXa, 30 nM A2 subunit, 250 nM factor X, and 25 M PL in TBS/BSA, pH 7.5, with 5 mM CaCl 2 . The reaction mixture for IXa R333Q contained 300 nM factor IXa instead of 100 nM used for IXa WT or IXa PCEGF1 ; concentrations of other components were the same. The amount of factor Xa generated was determined by hydrolysis of S-2222. The IC 50 values were obtained using Equation 2. Here, y is the rate of factor Xa formation in the presence of a given concentration of the A2 558 -565 peptide represented by x, and a is the maximum rate of factor Xa formation in the absence of the A2 peptide. Equation 3 was then used to obtain the apparent K d(peptide) values. Here, A is the concentration of IXa WT , IXa PCEGF1 , or IXa R333Q, and EC 50 is the apparent K d(A2) for the respective IXa:A2 subunit interaction.
Molecular Modeling-The three (A1, A2, and A3) domains in factor VIIIa are homologous to the three respective domains in ceruloplasmin (12, 38) . The A1, A2, and A3 domains of factor VIIIa were modeled using the coordinates of each respective domain of ceruloplasmin (39) . Each domain was modeled using the homology model building module from Biosym/MSI (San Diego, CA), as well as the Swiss-Model server using the optimize mode (40, 41) . The two approaches used in building the homology models resulted in minor differences between the structure of each of the A subunits. However, the structure pertaining to the loop containing the 3 10 helical turn involving residues 558 -565 as well as other nearby interface regions of the A2 subunit implicated in binding to factor IXa were invariant between the two models. Further, the Biosym/MSI models of all three A subunits were similar to those published previously by Pemberton et al. (12) . Thus, we used the coordinates of Pemberton et al. (Ref. 12 ; see hemophilia data base, available on-line) in building the interface between the A2 subunit and the protease domain of factor IXa. Details are provided under "Results and Discussion."
RESULTS AND DISCUSSION

Activation of Factor X by Various Factor IXa Proteins in the Presence of Only Ca
2ϩ and PL-The kinetic constants for the activation of factor X were obtained by various factor IXa proteins in the presence of Ca 2ϩ and several concentration of PL. This analysis was performed to establish whether or not the factor IXa proteins under investigation bind to Ca 2ϩ and PL normally and possess a functional active site. The kinetic constants obtained under these conditions in the absence of factor VIIIa are listed in Table I . All mutants activated factor X normally, and the specificity constant (kcat/K m ) for each mutant at different PL concentrations did not differ appreciably from that observed for IXa WT or IXa NP . The increase in K m values at higher concentrations of PL for WT or for a given mutant may reflect binding of factor IXa and factor X to different PL vesicles (42, 43) . Further, our K m and k cat values are in close agreement with the earlier published data (18, 43) . Consistent with earlier observations (43), we also observed a slight increase in k cat for each factor IXa protein at higher concentrations of PL. Cumulatively, our data presented in Table I Factor IXa:Factor VIIIa Interactionability of the A2 subunit to augment factor X activation by various factor IXa mutants. These data are presented in Fig. 1 . The presence of the A2 subunit in the reaction mixtures enhanced the factor X-activating activity of IXa PCEGF1 to the same extent as that of IXa WT . However, the ability of the A2 subunit to potentiate the activity of IXa R333Q was severely impaired, and it was essentially absent for IXa VIIhelix In further experiments, we measured the EC 50 values for interaction of IXa WT and of IXa PCEGF1 with the A2 subunit using different concentrations of factor X ranging from 50 nM to 5 M. These data are presented in Fig. 2 . At each concentration of factor X, the concentration of factor IXa was held constant at 5 nM and the rate of factor Xa generation was determined in the presence of increasing concentrations of the A2 subunit. The EC 50 values ranged from ϳ280 nM at lower concentrations of factor X (Ͻ150 nM) to ϳ200 nM at higher concentrations of factor X (Ͼ1 M) for both IXa WT and IXa PCEGF1 . Our functional K d (EC 50 ) values ranging from 200 to 280 nM for the interaction of IXa WT (or IXa PCEGF1 ) and the A2 subunit employing different factor X concentrations are consistent with the EC 50 values obtained earlier using similar conditions for IXa NP and the A2 subunit (18) . From these observations, we conclude that factor X does not appreciably influence the functional K d of IXa:A2 subunit interaction. This is in contrast to the results obtained using factor VIIIa where factor X reduces the functional K d of IXa:VIIIa interaction by ϳ10-fold (34). These results support previous observations that the A1 subunit of factor VIIIa interacts with factor X (23). More importantly, our data with the IXa PCEGF1 mutant indicate that the EGF1 domain of factor IXa does not interact with the A2 subunit of factor VIIIa. for IXa R333Q or IXa VIIhelix could not be calculated. These results suggest that the isolated A2 subunit interacts equivalently with IXa WT and IXa PCEGF1 , and similarly modulates the emission of the active site-labeled dansyl probe. The apparent K d(A2) value of ϳ82 nM for factor IXa WT or IXa PCEGF1 obtained using the fluorescence quenching measurements is in agreement with the values obtained from steady state inhibition experiments. Consistent with the data presented in Figs. 1 and 3 , these fluorescence results suggest that the factor IXa R333Q and IXa VIIhelix mutants are severely impaired in their interactions with the A2 subunit.
Determination of Apparent K d Peptide Values for Binding of Factor IXa Proteins to the A2 558 -565
Peptide-The data presented thus far strongly indicate that the A2 subunit interacts with residues of the helix 330 (c162) of factor IXa. Previous studies also suggest that residues 558 -565 of the A2 subunit are involved in binding to factor IXa (18) . However, it is not known whether the 558 -565 peptide region of the A2 subunit represents the site of direct interaction with the helix 330 of factor IXa. We investigated this possibility by measuring the affinity of the A2 558 -565 peptide for IXa WT , IXa PCEGF1 , and IXa R333Q . These data are presented in Fig. 5 . The A2 558 -565 peptide inhibits the interaction of IXa WT and IXa PCEGF1 with similar IC 50 values of ϳ8 M. 4 However, the A2 558 -565 peptide inhibited the IXa R333Q :A2 subunit interaction with an IC 50 value of ϳ70 M, which is ϳ9-fold higher than the value obtained for IXa WT or IXa PCEGF1 (Fig. 5) . We next used the Cheng and Prusoff relationship (36, 37) (Table II) . This difference in ⌬G 0 is essentially the same as that (1.62 kcal mol Ϫ1 ) obtained for the interaction of A2 peptide with IXa WT (or IXa PCEGF1 ) and IXa R333Q . If the A2 558 -565 peptide bound to a different region than the helix 330 of factor IXa, then one would expect it to bind to IXa R333Q with the same affinity as that for IXa WT . Since this is not the case, our data support a conclusion that the helix 330 (c162) in factor IXa is most likely in direct contact with the 558 -565 region of the A2 subunit.
Modeling of the Interface between the Protease Domain of Factor IXa and the A2 Subunit of Factor VIIIa-Based upon the preceding information, we modeled the interface between the protease domain of factor IXa (Ref. 5, Protein Data Bank code 1RFN) and the A2 subunit (see "Experimental Procedures") by bringing together the helix 330 of factor IXa and the 3 10 helical turn in residues 558 -565 of the A2 subunit and maximizing the interaction among the charged residues. Emphasis was also given for interactions involving hydrogen bonds and hydrophobic contacts. An important guiding principle in the construction of this interface model was that the Gla domain of factor IXa and the C2 domain of factor VIIIa must be oriented such that each may contact the PL surface. To achieve this, the A2 structure (along with the A1 and A3 subunits) was rotated and translated as a rigid body. The principle approach used was that described earlier by Tulinsky and co-workers (44) in building the prothrombin model from the structures of prothrombin fragment 1 and the fragment 2-thrombin complex. Minor adjustments in the side chains of both proteins were also made. All residues in the interface of both proteins were checked for distances to ensure no improper contacts (45) . The interface model that resulted from this approach is shown in Fig. 6A . In this display, the Gla domain of factor IXa and the C2 domain of factor VIIIa are projecting away from the viewer.
In addition to the A2 558 -565 region and the factor IXa 330 -338 region, other spatially nearby regions that may play important roles in the interaction of A2 subunit with the protease domain were also noted. The details of the composite interface region are shown in Fig. 6B . It appears that electrostatic forces might play a significant role in the interaction between the A2 subunit and the protease domain, and an electrostatic potential for the interface calculated using the program GRASP (46) is shown in Fig. 6C . Further, in addition to the electrostatic interactions outlined in Fig. 6 Thus, it appears that the hydrogen bonds as well as the hydrophobic and electrostatic interactions all play important roles in the proposed interface between factor IXa and the A2 subunit. In this context, an apparent K d(A2) of ϳ100 nM observed for this interaction reflects the net change in free energy involved in making and breaking such bonds.
A factor IXa-interactive site comprising residues 484 -509 in the A2 subunit that was identified using a monoclonal antibody (47) does not appear to contact the protease domain in our interface model. However, it should be noted that, in a previous study (48) , Lollar et al. concluded that this same monoclonal antibody does not interfere with the IXa:VIIIa interaction. The Fig. 6 . Interface model between the factor IXa protease domain and the A2 subunit of factor VIIIa. The coordinates for the human factor IXa structure are from the Brookhaven Protein Data Bank (code 1RFN) and the coordinates for the A1, A2, and A3 subunits (12) of factor VIIIa are based upon homology models built using ceruloplasmin coordinates (Protein Data Bank code 1KCW). A, schematic representation of the interface model. Ribbon structure for each protein is depicted. The IXa protease domain is in light blue, and the EGF2 domain is in red. The A1 subunit is in yellow, the A2 subunit is in magenta with residues 484 -509 in white, and the A3 subunit is in cyan with the COOH terminus in red. The Gla and the EGF1 domains of factor IXa and the C1 and C2 domains of factor VIIIa are not shown. The interface residues of factor IXa protease domain and of the A2 subunit are shown as CPK space-filling models. The molecules are oriented such that the Gla domain of factor IXa and the C2 domain of factor VIIIa are projecting away from the viewer. The Gla domain in factor IXa and the C2 domain of factor VIIIa bind to the PL surface. B, detailed interface between factor IXa protease domain and the modeled A2 subunit. Only the charged residues that participate in the binding interactions are depicted. The hydrophobic residues that participate in this interaction are discussed in the text. The orientation of the molecules is the same as in A. Chymotrypsin numbering system for the factor IXa protease domain is used. Corresponding factor IX numbering system are 338 (c170), 332 (c164), 333 (c165), 346 (c178), 403 (c233), 293 (c126), and 410 (c240). Factor IXa residues are labeled light blue, and A2 subunit residues are labeled magenta. C, electrostatic potential between the factor IXa protease domain and the A2 subunit interface as determined using the program GRASP (46) . Blue represents positive, red represents negative, and white represents neutral residues.
reason(s) for the differing results obtained in the two studies (47, 48) is not fully understood. Further, in the proposed interface model shown in Fig. 6A , the 484 -509 region in the A2 subunit is not in close proximity to the 558 -565 interface region and shows no apparent contacts with factor IXa. However, we cannot exclude the possibility of a change in the conformation of the A2 subunit upon binding the protease domain, which may juxtapose (and subsequently involve) this region. Alternatively, the monoclonal antibody may prevent the association of the A2 subunit with factor IXa through steric interference.
Analysis of Hemophilia Data Bases-Of significance is the observation that numerous mutations in the helix 330 (c162) of factor IXa cause hemophilia B (see Ref. 25 and the Haemophilia B data base of point mutations and short additions and deletion), whereas several mutations in or near factor VIII residues 558 -565 result in hemophilia A (Ref. 12; see hemophilia data base, available on-line). Arg 333 (c165) in our interface model (Fig. 6) Concluding Remarks-Previous studies have indicated that the helix 330 (c162) of the protease domain (25) and 558 -565 region of the A2 subunit (18) represent important determinants for the interaction of factor IXa and factor VIIIa, respectively. However, it was not known whether these two regions interact with each other in the IXa:VIIIa complex. The present study provides evidence that these two regions may form an interface and interact with each other involving hydrophobic as well as electrostatic forces (Fig. 6) . Modeling of the interface suggests that other spatially nearby regions may also participate in the interaction of factor IXa with factor VIIIa. Several mutations in the proposed interface cause hemophilia A or B and are known to impair IXa:VIIIa interaction. Thus, our interface model is compatible with the existing biochemical as well as with the two-dimensional electron crystallography data of Stoylova et al. (20) . However, the three-dimensional cocrystal structure of the factor IXa protease domain and A2 subunit will be required to fully establish this view. In light of these considerations, we emphasize that our interface model is an interim model subject to refinement as new biochemical and experimentally determined structural data become available.
